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Abstract
Thyroid function disorders affect between 5% and 15% of patients treated with IFNa and RBV for chronic hepatitis C. Women and pa-
tients with thyroid peroxidase antibodies (TPOAb) found before the treatment are at risk of developing the disorders (46.1% vs. 5.4%). 
The spectrum of IFNa-induced thyroiditis (IIT) includes two groups. Disorders with an autoimmune background are: presence of thyroid 
autoantibodies without clinical disease, Hashimoto’s disease and Graves’ disease. The second group comprises diseases caused by the 
direct toxic effect of IFNa on the thyroid gland, i.e. destructive thyroiditis and non-autoimmune hypothyroidism. Thyroid diseases are 
not an absolute contraindication for IFNa and RBV therapy. In patients diagnosed with thyroid dysfunction, before the antiviral therapy 
it is necessary to achieve euthyreosis. Thyroid function disorders may occur at any moment of the therapy. The earliest have been ob-
served in the 4th week of treatment, and the latest 12 months after its termination. During the therapy, in order to diagnose IIT early, it is 
recommended to determine TSH level every 2–3 months depending on the presence of TPOAb before the treatment. The diagnosis and 
treatment of thyroid function disorders should be conducted in co-operation with an endocrinologist. (Pol J Endocrinol 2012; 63 (1): 66–70)
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Streszczenie
Zaburzenia funkcji tarczycy dotyczą 5 do 15% leczonych IFNa i RBV z powodu przewlekłego zapalenia wątroby typu C. Zagrożone ich 
wystąpieniem są kobiety oraz chorzy, u których stwierdzono przed leczeniem obecność przeciwciał przeciwko tyreoperoksydazie (TPOAb) 
(46,1% v. 5,4%). Spektrum zapaleń tarczycy wywołanych przez IFNa (IIT) obejmuje dwie grupy. Do zaburzeń o podłożu autoimmunolo-
gicznym zalicza się: obecność przeciwciał przeciwtarczycowych bez objawów klinicznych choroby tarczycy, chorobę Hashimoto i chorobę 
Gravesa. Drugą grupę stanowią choroby spowodowane bezpośrednim toksycznym działaniem IFNa na tarczycę, tj. destrukcyjne zapalenie 
tarczycy, nieautoimmunologiczna niedoczynność tarczycy. Choroby tarczycy nie są bezwzględnym przeciwwskazaniem do leczenia IFNa 
i RBV. U chorych z rozpoznaną przed rozpoczęciem terapii przeciwwirusowej dysfunkcją tarczycy należy uzyskać eutyreozę. Zaburzenia 
funkcji tarczycy mogą się pojawić w każdym momencie terapii. Najwcześniej obserwowano ich rozwój w 4. tygodniu leczenia, najpóźniej 
12 miesięcy po jego zakończeniu. W czasie terapii w celu szybkiego wykrycia IIT zaleca się oznaczanie TSH co 2 lub 3 miesiące, w zależności 
od obecności TPOAb przed leczeniem. Diagnostyka i leczenie zaburzeń funkcji tarczycy powinny być prowadzone przy współudziale 
lekarza endokrynologa. (Endokrynol Pol 2012; 63 (1): 66–70)
Słowa kluczowe: interferon alfa, przewlekłe zapalenie wątroby typu C, zapalenie tarczycy wywołane przez interferon, przeciwciała 
przeciwtarczycowe
Introduction
Interferons are divided into three major types depend-
ing on their properties and ability to bind to particular 
kinds of receptors. Interferons a, b and w belong to 
type I, and interferon g represents type II. Interferon 
l-1, undergoing the first phase of clinical trials, is clas-
sified as type III [1, 2]. There are at least 12 types of 
interferon alpha (IFNa). It has been used in the treat-
ment of chronic hepatitis C since the 1990s. Initially, 
it was used in the recombinant form (rIFNa) and in 
monotherapy, and more recently in combination with 
ribavirin (RBV) and in pegylated form (PegIFNa). Other 
forms of this cytokine, i.e. natural leukocyte interferon 
alpha, interferon alpha conjugated to albumin, or inter-
feron alpha consensus-1, which is a mixture of natural 
and recombinant interferons, are less frequently used.
Therapy with IFNa causes various undesirable ef-
fects. Some of them, such as fever, muscle and joint pain, 
and haematological disorders, occur in the initial period 
of the therapy. Other effects, such as mood disorders 
and hair loss take place later. From 5% to 15% of patients 
treated with IFNa for chronic hepatitis C may develop 
thyroid function disorders, and in 40% of the patients 
thyroid autoantibodies (TAbs) may appear without 
clinical disease [3–5]. The relationship between the 
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cytokine and thyroid dysfunction was first described 
in 1985 in patients treated because of neoplasms i.e. 
breast cancer [6, 7].
Factors predisposing to development 
of thyroid function disorders
The risk of developing thyroid function disorders con-
cerns women (they have a four times higher risk than 
men) and patients with thyroid peroxidase antibodies 
found before the treatment (46.1% vs. 5.4%) [5, 8]. Pa-
tients undergoing interferon and ribavirin combination 
therapy develop autoimmune hypothyroidism more 
often than patients receiving interferon monotherapy 
[9]. Destructive thyroiditis occurs more frequently in 
patients treated with interferon alpha consensus-1 than 
in patients treated with rIFNa. This fact is related to 
a strong, direct, cytotoxic effect of the first interferon on 
thyreocytes. However, there is no difference between 
rIFNa and PegIFNa [10]. Some research has suggested 
that higher doses of IFNa and longer therapy create 
favourable conditions for the occurrence of thyroid 
dysfunction [8], but analyses of other research results 
do not confirm this suggestion [11–13]. 
Data concerning the relationship between HCV 
infection and thyroid function disorders also di-
verges. Fernandez-Soto showed that 20–42% of HCV 
infected patients had TAbs, compared to 5–10% of those 
infected with HBV. According to the author, this proves 
that such a relationship exists [14]. In their study, Mara-
zuela et al. estimated the incidence of TPOAb in HCV 
infected patients to be 14.7%, which is similar to that in 
the healthy population [15].
Clinical spectrum of IFNa-induced thyroid 
function disorders
Autoimmune interferon induced thyroiditis 
(autoimmune IIT)
Presence of thyroid autoantibodies without clinical 
manifestations of thyroid disease
Patients treated with IFNa are most often found positive 
for TAbs, mainly thyroid peroxidase antibodies and/or 
thyroglobulin antibodies (TgAb) without clinical dise-
ase. It is commonly believed that their presence, and that 
of TPOAb in particular, indicates the presymptomatic 
phase of autoimmune thyroiditis. The titre of antibodies 
may rise during IFNa therapy if they are found before 
the treatment [3, 4]. The risk of developing clinically 
apparent disease, particularly in women with goitre 
and antibodies, amounts to 5% per year [16, 17]. Thy-
roid autoantibodies can be produced during IFNa de 
novo therapy in 1.9–40% of patients [3, 4, 13, 18]. The 
phenomenon is more frequently observed in women 
than in men (14.8% vs. 1%) and is also associated with 
increasing age [13]. In most patients, TAbs are detected 
after the termination of IFNa therapy [19].
Hashimoto’s thyroiditis (HT) 
Hashimoto’s thyroiditis is the commonest clinical 
manifestation of autoimmune IIT and occurs in 2.4% to 
19% of patients treated with IFNa. A factor increasing 
the risk of HT development is the presence of TPOAb 
before IFNa therapy [4, 8, 13, 18]. TPOAb titre often 
increases during the therapy [4]. The disease manifests 
itself through subclinical hypothyroidism (elevated 
TSH level, normal fT4 level) or clinically apparent hy-
pothyroidism (elevated TSH, low fT4). Goitre occurs in 
some patients. The disease is diagnosed on the basis of 
hypothyroidism symptoms and the presence of TPOAb 
and/or TgAb. Supplementation of thyroid hormones is 
used in the treatment. Hashimoto’s thyroiditis rarely be-
comes the reason for premature termination of therapy 
with IFNa and RBV.
Graves’ disease (GD)
IFNa leads to the development of GD in people predis-
posed to it (immunogenetic background) [3, 20]. Its rare 
occurrence during IFNa therapy is explained by the sup-
pressive effects of IFNa on the immune response depen-
dent on Th2 lymphocytes. In patients with Graves’ disease, 
they stimulate B lymphocytes to produce TSH receptor 
antibodies (TRAb). The antibodies stimulate the activity 
of follicular cells, which results in thyroid hormone secre-
tion. IFNa inhibits this signal transduction pathway [16]. 
Physical examination shows hyperthyroidism symptoms 
and goitre. Graves’ ophthalmopathy develops rarely, and 
may lead to half-closed eyes during sleep and keratitis 
or optic nerve compression causing visual impairments 
[21, 22]. Laboratory tests show a characteristic decrease 
in TSH level, increase in fT4 and fT3 levels, and the pres-
ence of TRAb. Iodine uptake is normal or increased. Most 
GD cases do not undergo remission after completion of 
IFNa therapy.
Non-autoimmune IIT
TAbs do not occur in around 50% of patients with 
thyroid function disorders during IFNa therapy. This 
fact indicates the direct toxic effect of IFNa on thyroid 
cells, without the participation of immunological factors 
[3, 20, 23]. There are two recognised clinical forms of 
non-autoimmune thyroiditis.
Destructive thyroiditis (DT)
Destructive thyroiditis is diagnosed in over half of the 
patients developing hyperthyroidism during IFNa 
therapy [3, 4, 23]. It is a self-limited inflammatory 
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disease of the thyroid gland which has three phases. The 
first phase is characterised by sudden onset and hy-
perthyroidism symptoms, sometimes accompanied by 
fever and neck tenderness. After several days or weeks, 
hypothyroidism develops, which is characteristic for 
the second phase of the disease. Over the following 
weeks and months, the thyroid gland restores its normal 
function (the third phase). Fewer than 5% of patients 
develop long-term hypothyroidism [24]. Sometimes 
the course of the disease is very mild and its symptoms 
remain unnoticed or are interpreted as undesirable ef-
fects of interferon. In many cases, spontaneous recovery 
takes place. Diagnosis of DT in IFNa treated patients is 
based on the lack of TRAb, TPOAb and low radioactive 
iodine uptake [3, 20].
Non-autoimmune hypothyroidism
This is a transient subclinical or clinically apparent hy-
pothyroidism running its course without the presence of 
TAbs. If the disease lasts longer, thyroid autoantibodies 
appear, which indicates the secondary role of immuno-
logical factors [3, 15, 20].
The criteria for a diagnosis of thyroid function dis-
orders developed during IFNa and RBV therapy are 
presented in Table I.
Assessment of suitability of chronic hepatitis C 
patients for IFNa and RBV treatment
Assessment of suitability for the treatment should 
include:
 — thorough patient interview (thyroid diseases in 
the patient and his/her close relatives) and physi-
cal examination (symptoms of hyperthyroidism or 
hypothyroidism);
 — determination of TSH, fT4, TAbs: TPOAb, TgAb, 
and also TRAb and fT3 in the case of thyrotoxicosis.
The aim is to identify patients with subclinical hy-
pothyroidism or hyperthyroidism, apparent thyroid 
disease and a heightened risk of developing thyroid 
function disorders during the therapy. Thyroid dise-
ases are not absolute contraindications for IFNa and 
RBV treatment. Patients previously diagnosed with 
thyroid dysfunction must be in euthyreosis before the 
treatment begins.
Principles of monitoring and early diagnosis 
of thyroid dysfunction during IFNa and RBV 
treatment
Thyroid function disorders can occur at any moment 
of the therapy. The earliest have been observed in the 
4th week of treatment, and the latest 12 months after its 
termination (in the case of a 48-week therapy) [25, 26]. 
During the treatment, TSH level should be determined 
every 2–3 months depending on the presence of TAbs 
before the treatment [3, 13, 21]. Details are shown in Fig-
ure 1. Clinicians should routinely examine for signs of 
thyroid dysfunction such as tachycardia or bradycardia, 
heat or cold intolerance, and unexpected weight change. 
If the patient develops abnormal thyroid functions 
while on IFNa, a full work-up needs to be completed.
Table I. Main diagnostic criteria for thyroid dysfunction associated with IFNa and RBV treatment
Tabela I. Diagnostyka zaburzeń funkcji tarczycy występujących podczas terapii IFNa i RBV
Tests Autoimmune interferon-induced thyroiditis Non-autoimmune interferon-induced 
thyroiditis
Hashimoto’s thyroiditis Graves’ disease Destructive 
thyroiditis
Non-autoimmune 
hypothyroidism
TSH level ≠ Ø 1st phase Ø
2nd phase ≠
3rd phase normal
≠
fT4 level Normal or Ø Normal or ≠ 1st phase normal or ≠
2nd phase normal or Ø
3rd phase normal
Normal or Ø
TPOAb (+) (–) or (+) (–) (–)
TgAb (+) or (–) (–) (–) (–)
TRAb (–) (+) (–) (–)
Goitre present Yes or no Yes Yes or no No
Thyroid ultrasound/
/scintigraphy
Decreased echogenicity/
/lack of clinical practice
Decreased echogenicity/
/increased or normal uptake 
of J131 on thyroid scan
Diffuse echogenicity/
/reduced uptake of J131 
on thyroid scan
–
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Treatment of thyroid function disorders
The treatment of thyroid disease should be conducted 
in co-operation with an endocrinologist. Endocrine 
consultation is recommended for all patients diagnosed 
with thyroid dysfunction.
Hyperthyroidism occurs less frequently than hy-
pothyroidism [26]. Anti-thyroid drugs (ATD) used in 
therapy can intensify IFNa–induced neutropenia or 
cause agranulocytosis. One should also remember the 
hepatotoxic effects of the drugs. Derivatives of both 
imidazole and thiouracyl can cause drug-induced liver 
injuries. Thiamazole mainly induces dose-dependent 
cholestasis, while propylthiouracyl induces dose-in-
dependent hepatitis. 
Due to these undesirable effects, some authors do 
not recommend the administration of these drugs to 
patients with IFNa–induced Graves’ disease [27]. In 
a case of continuation of antiviral therapy, the patient 
must be kept under close observation. If it is necessary 
to use other methods of treatment (e.g. radioactive 
iodine J131, strumectomy), IFNa and RBV therapy must 
be discontinued [20, 21]. 
When destructive thyroiditis is suspected, it is rec-
ommended to administer beta blockers and perform 
TSH and fT4 tests frequently. It is not advised to use 
ATD in the first phase of the disease, because its second 
phase is hypothyroidism.
In the treatment of hypothyroidism, thyroid hor-
mone supplementation is used according to commonly 
accepted principles. Treatment tolerance is usually 
good. Hypothyroidism rarely becomes the reason for 
premature termination of antiviral therapy. During the 
treatment, TSH and fT4 levels should be determined 
every two months [13, 20].
A decision to use glucocorticosteroids in IFNa-in-
duced thyroid diseases must be taken individually. 
The period of time when the steroids are used should 
be as short as possible, as they intensify HCV replica-
tion [20].
An absolute indication to discontinue treatment is 
a life-threatening condition such as hypermetabolic 
crisis, myxoedema coma, or agranulocytosis. In other 
cases, the decision to terminate therapy should be taken 
jointly by the doctor treating the chronic hepatitis C 
patient and the endocrinologist.
Conclusions
Thyroid function disorders are not frequent complica-
tions of therapy with interferon alpha and ribavirin. 
They may, however, sometimes be the reason for its 
premature termination. The possibility of the disorder’s 
occurrence must be taken into account, particularly 
when weight loss and/or hair loss are observed in the 
patient and he/she reports touchiness, emotional 
imbalance, memory disorders, general weakness, or 
decreased exercise tolerance. These complaints, often 
associated with the effects of IFNa and RBV, are in fact 
early symptoms of thyroid disease. 
Thyroid function disorders are not an absolute 
contraindication for antiviral treatment, but euthyreo-
sis should be achieved before beginning the therapy. 
Special attention should be paid to patients with TPOAb 
present before the treatment. Due to a higher risk of 
developing thyroid dysfunction, patients require close 
monitoring during the therapy. Only sound co-op-
eration between the doctor conducting the antiviral 
therapy and an endocrinologist can ensure proper 
preparation of the patient with thyroid pathology for 
therapy, and its safe course.
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